# US 2017/0281736 A1 · Cholix toxin-derived fusion moelcules for oral delivery of biologically active cargo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281736 A1
- Document ID: US20170281736A1
- Status: Published application
- Kind: A1
- Application number: 15/616,140
- Filed: 2017-06-07
- Published: 2017-10-05
- Earliest claimed: 2014-05-07
- Assignees: Applied Molecular Transport Inc.
- Applicants: Applied Molecular Transport, LLC
- Inventors: Randall Mrsny; Tahir Mahmood
- Web page: https://patentgrep.com/patent/US20170281736A1

## CPC

- A61K 38/45: Transferases (2)
- A61K 38/164: {from bacteria}
- A61K 38/166: {Streptokinase}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/20: Interleukins [IL]
- A61K 38/2066: {IL-10}
- A61K 38/26: Glucagons
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 38/49: Urokinase; Tissue plasminogen activator
- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 38/51: Lyases (4)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/12: Antidiarrhoeals
- A61P 17/06: Antipsoriatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/5428: {IL-10}
- C07K 16/241: {Tumor Necrosis Factors}
- C12Y 204/02036: NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
- C12Y 304/21068: Tissue plasminogen activator (3.4.21.68), i.e. tPA
- C12Y 304/21073: u-Plasminogen activator (3.4.21.73), i.e. urokinase
- C12Y 305/04004: Adenosine deaminase (3.5.4.4)
- C12Y 402/02001: Hyaluronate lyase (4.2.2.1)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K 2319/50: containing protease site
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C07K 2319/90: containing a motif for post-translational modification
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. The systems and methods described herein provide for: the ability to deliver macromolecule doses without injections; the ability to deliver cargo such as siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes.

## Claims

### Claim 1

A pharmaceutical composition comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, wherein the fusion molecule comprises a modified Cholix toxin coupled to a biologically active cargo, wherein the modified Cholix toxin is mutated at an amino acid residue within Cholix toxin domain III that renders the Cholix toxin non-toxic, and wherein the fusion molecule has the ability to activate the receptor for the biologically active cargo, or to enable the catalytic process of a catalytically-active material.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the modified Cholix toxin comprises the amino acid sequence set forth in SEQ ID NO: 81.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the biologically active cargo is a macromolecule, small molecule, peptide, polypeptide, nucleic acid, mRNA, miRNA, shRNA, siRNA, antisense molecule, antibody, DNA, plasmid, vaccine, polymer nanoparticle, or catalytically-active material.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the modified Cholix toxin is directly coupled to the biologically active cargo.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the biologically active cargo is directly coupled to the C-terminus of the modified Cholix toxin.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the modified Cholix toxin is chemically coupled to the biologically active cargo.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the modified Cholix toxin is coupled to the biologically active cargo by a non-cleavable linker, wherein the modified Cholix targets said cargo to specific cells, including cells of the immune system such as macrophages, antigen-presenting cells and dendritic cells.

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the modified Cholix toxin is coupled to the biologically active cargo by a cleavable linker.

### Claim 9

A method for delivering a therapeutic cargo to a subject, the method comprising orally administering to the subject a pharmaceutical composition comprising a non-toxic Cholix toxin coupled to a therapeutic cargo.

### Claim 10 (depends on 9)

The method of claim 9, wherein the modified Cholix toxin comprises the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 81.

### Claim 11 (depends on 9)

The method of claim 9, wherein the biologically active cargo is a macromolecule, small molecule, peptide, polypeptide, nucleic acid, mRNA, miRNA, shRNA, siRNA, antisense molecule, antibody, DNA, plasmid, vaccine, polymer nanoparticle, or catalytically-active material.

### Claim 12 (depends on 9)

A method of claim 9, wherein the modified Cholix toxin is directly coupled to the biologically active cargo.

### Claim 13 (depends on 9)

The method of claim 9, wherein the biologically active cargo is directly coupled to the C-terminus of the modified Cholix toxin.

### Claim 14 (depends on 9)

The method of claim 9, wherein the modified Cholix toxin is chemically coupled to the biologically active cargo.

### Claim 15 (depends on 9)

The method of claim 9, wherein the modified Cholix toxin is coupled to the biologically active cargo by a non-cleavable linker, wherein the modified Cholix targets said cargo to specific cells, including cells of the immune system such as macrophages, antigen-presenting cells and dendritic cells.

### Claim 16 (depends on 9)

The method of claim 9, wherein the modified Cholix toxin is coupled to the biologically active cargo by a cleavable linker.
